Literature DB >> 11375334

Protein metabolism in clinically stable adult cystic fibrosis patients with abnormal glucose tolerance.

A Moran1, C Milla, R Ducret, K S Nair.   

Abstract

Cystic fibrosis (CF) patients are reported to experience chronic protein catabolism. Since diabetes or impaired glucose tolerance (IGT) is common in CF, we hypothesized that their protein catabolic state is related to reduced insulin secretion or reduced insulin action. A total of 12 clinically stable adult CF patients with abnormal glucose tolerance and 12 age-, sex-, and lean body mass-matched healthy control subjects underwent protein turnover studies using L-[1-(13)C]leucine, L-[(15)N]phenylalanine, and L-[(2)H(4)]tyrosine, with and without exogenous insulin infusion. In the baseline fasting state, protein metabolism was entirely normal in CF patients, with no evidence of increased protein catabolism. In contrast, striking abnormalities were seen in CF patients when insulin was infused, since they did not experience normal suppression of the appearance rates of leucine, phenylalanine, or tyrosine (indexes of protein breakdown). At an insulin concentration of 45 +/- 2 microU/ml, normal control subjects suppressed the leucine appearance rate by 19 +/- 5% (P < 0.01), ketoisocaproate appearance rate by 10 +/- 3% (P = 0.03), tyrosine appearance rate by 11 +/- 2% (P = 0.03), and phenylalanine appearance rate by 6 +/- 3% (P = 0.07). Phenylalanine conversion to tyrosine decreased by 22 +/- 7% (P = 0.03). At a similar insulin concentration of 44 +/- 3 microU/ml, normal suppression of amino acid appearance did not occur in CF. The leucine appearance rate decreased by 4 +/- 2% (P = 0.65), ketoisocaproate appearance rate by 1 +/- 2% (P = 0.94), tyrosine appearance rate by 0 +/- 6% (P = 0.56), phenylalanine appearance rate by 5 +/- 6% (P = 0.34), and phenylalanine conversion to tyrosine by 5 +/- 6% (P = 0.95). Poor suppression of the amino acid appearance rate in CF was not related to previously documented glucose tolerance status (IGT or CF-related diabetes without fasting hyperglycemia), fasting insulin levels, the acute insulin response, insulin sensitivity, cytokine or counterregulatory hormone levels, resting energy expenditure, caloric intake, pulmonary function, or clinical status. Protein synthesis was not significantly affected by insulin infusion in either normal control subjects or CF patients. In conclusion, clinically stable adult CF patients have normal indexes of protein breakdown and synthesis in the fasting state. In contrast, elevation of plasma insulin to physiological postprandial levels fails to normally suppress indexes of protein breakdown. It is therefore likely that inability to spare protein during the postprandial state is the cause of protein catabolism in these patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11375334     DOI: 10.2337/diabetes.50.6.1336

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  21 in total

Review 1.  Understanding cystic-fibrosis-related diabetes: best thought of as insulin deficiency?

Authors:  Lee Dobson; Christopher D Sheldon; Andrew T Hattersley
Journal:  J R Soc Med       Date:  2004       Impact factor: 5.344

2.  Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance.

Authors:  C Bizzarri; V Lucidi; P Ciampalini; S Bella; B Russo; M Cappa
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

3.  Insulin secretion abnormalities in exocrine pancreatic sufficient cystic fibrosis patients.

Authors:  Jamie L Wooldridge; Rhonda D Szczesniak; Matthew C Fenchel; Deborah A Elder
Journal:  J Cyst Fibros       Date:  2015-03-06       Impact factor: 5.482

4.  Stimulated nitric oxide production and arginine deficiency in children with cystic fibrosis with nutritional failure.

Authors:  Mariëlle P K J Engelen; Gulnur Com; Yvette C Luiking; Nicolaas E P Deutz
Journal:  J Pediatr       Date:  2013-02-15       Impact factor: 4.406

5.  Oral glucose tolerance testing in children with cystic fibrosis.

Authors:  Katie Larson Ode; Brigitte Frohnert; Theresa Laguna; James Phillips; Bonnie Holme; Warren Regelmann; William Thomas; Antoinette Moran
Journal:  Pediatr Diabetes       Date:  2010-11       Impact factor: 4.866

6.  Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial.

Authors:  Antoinette Moran; Penelope Pekow; Patricia Grover; Martha Zorn; Bonnie Slovis; Joseph Pilewski; Elizabeth Tullis; Theodore G Liou; Holley Allen
Journal:  Diabetes Care       Date:  2009-07-10       Impact factor: 17.152

7.  Impaired fasting glucose in cystic fibrosis.

Authors:  Brigitte I Frohnert; Katie Larson Ode; Antoinette Moran; Brandon M Nathan; Theresa Laguna; Bonnie Holme; William Thomas
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

Review 8.  Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review.

Authors:  Antoinette Moran; Dorothy Becker; Samuel J Casella; Peter A Gottlieb; M Sue Kirkman; Bruce C Marshall; Bonnie Slovis
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

9.  Body composition and lung function in cystic fibrosis and their association with adiposity and normal-weight obesity.

Authors:  Jessica A Alvarez; Thomas R Ziegler; Erin C Millson; Arlene A Stecenko
Journal:  Nutrition       Date:  2015-10-30       Impact factor: 4.008

10.  Dietary essential amino acids are highly anabolic in pediatric patients with cystic fibrosis.

Authors:  Mariëlle P K J Engelen; Gulnur Com; Robert R Wolfe; Nicolaas E P Deutz
Journal:  J Cyst Fibros       Date:  2013-01-26       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.